00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
14:01 , Oct 18, 2018 |  BC Extra  |  Company News

Xyphos, Parker Institute steer next-gen CAR T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertibleCAR platform. Xyphos President and CEO Jim Knighton told BioCentury the research will...
20:08 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Cell culture and mouse studies suggest a bispecific antibody against SLAMF7 and NKG2D could help treat SLAMF7-expressing MM. The bispecific antibody consists of a single-chain variable fragment (scFv) targeting SLAMF7 expressed...
01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
17:48 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Innate reports Phase I data for monalizumab plus Imfinzi in CRC

Innate Pharma S.A. (Euronext:IPH) reported preliminary data from 37 evaluable patients with recurrent, metastatic, microsatellite-stable colorectal cancer (MSS-CRC) in an expansion portion of a Phase I trial showing that monalizumab (IPH2201) plus Imfinzi durvalumab from...
20:38 , May 17, 2018 |  BC Innovations  |  Emerging Company Profile

Beyond B cells

PureTech Health plc subsidiary Vor Biopharma Inc. plans to combine CAR T therapies with hematopoietic stem cells modified to go unrecognized by CAR Ts. The approach could increase the types of immune cells that can...
21:12 , May 9, 2018 |  BC Innovations  |  Translation in Brief

The fate of NK cells

New research is elucidating the relationship between CAR-transfected NK cells’ differentiation states and their cancer-killing potential -- knowledge that Fate Therapeutics Inc. (NASDAQ:FATE) is leveraging for its own cell therapies. In a study published in Cancer...
18:54 , Mar 15, 2018 |  BC Innovations  |  Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...